Clinical trial
A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide
NCT00759824 is registered in ClinicalTrials.gov with European Lung Cancer Working Party as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide
- Lead sponsor
- European Lung Cancer Working Party
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2008
- Completion date
- June 30, 2014
- Enrollment
- 64 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.